Patients in the advanced-stage had significantly lower 5-year survival rate compared with those in the early-stage (stage IV, 5% versus stage I 95%) [4], but CRC was difficult to diagnose at early stage due to a lack of typical symptoms as well as specific and sensitive cancer biomarkers, for example, carcinoembryonic antigen (CEA). This evidence concerns the gene CEACAM5 and cancer.